Perrigo(US:PRGO)2026-02-26 14:32Financial Data and Key Metrics Changes - For the full year 2025, the company reported a 2% increase in operating income and a 7% increase in EPS, finishing at $2.75, aligning with revised guidance [8][4] - CORE Perrigo operating income increased by 7%, with CORE EPS up 14% [8] - In Q4 2025, CORE organic net sales declined by 2%, with CORE operating income down by $4 million or 2%, resulting in CORE EPS of $0.76, a decline of $0.02 [8][11] Business Line Data and Key Metrics Changes - CSCI's full year core organic net sales decreased by 0.2%, while fourth quarter core organic net sales decreased by 1.4% due to consumer softness in the OTC category [17] - CSCA's full year core organic net sales increased by 3%, but fourth quarter core organic net sales decreased by 2.4%, driven by lower contract manufacturing revenue [18] - All-in net sales for the quarter and full year included declines in infant formula net sales of approximately 25% and 10% respectively [18] Market Data and Key Metrics Changes - The U.S. OTC market dollar sales were down 5.1% over the last 13 weeks compared to the previous year, with a 4.3% decline in Q4 and a 1.2% decline for the full year 2025 [11] - Despite market challenges, the company gained solid market share across most categories, reversing years of decline [5][6] Company Strategy and Development Direction - The company is focused on its Three-S plan to simplify, streamline, and strengthen the business, with new reporting segments to be introduced in Q1 2026 [4][10] - The strategy includes enhancing consumer-centric innovation, demand generation, and targeted geographic expansion [12][14] - The company aims to grow share in key brands and deliver on its innovation pipeline while managing costs effectively [14][22] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, expecting temporary headwinds but confident in long-term growth and value creation [5][12] - The company anticipates CORE Perrigo organic net sales growth in 2026 to range from -3.5% to +0.5%, with core EPS projected between $2.25 and $2.55 [12][22] - Management highlighted the importance of addressing under absorption and operational enhancements to improve margins and cash flow [40][41] Other Important Information - The company reported a goodwill impairment charge of $1.3 billion for 2025, which does not impact strategy or cash flows [15] - A new operational enhancement program is expected to deliver annualized pre-tax savings of $80 million to $100 million, with a global workforce reduction of approximately 7% [22][23] Q&A Session Summary Question: Outlook for 2026 and pressures in the first half - Management indicated that the decline is largely transitory, with expectations for stabilization and share growth in the second half of 2026 [30][31] Question: Update on liquidity and leverage position - The company plans to use proceeds from the dermacosmetics sale to reduce debt while maintaining dividend commitments [34] Question: Recovery of margins in the OTC business - Management expects margin recovery to be transitory, with improvements anticipated in the second half of 2026 and into 2027 [40] Question: Path to normalizing operations and margins in the infant formula business - The strategic review is ongoing, with various options being assessed, including potential partnerships and divestments [42] Question: Categories with negative growth driving guidance - Preventative categories are performing better, while cough, cold, and certain pain segments are currently weaker [46] Question: Capital allocation and dividend priorities - The company remains committed to its capital allocation priorities, focusing on business investment, reducing leverage, and maintaining dividends [49]